Beam Therapeutics (BEAM) | Stock Overview & Key Data
Beam Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $138.52 on June 28, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Beam Therapeutics
BEAM
|
3.10B Mid-cap | -7.34% | -1.76% | 8.56% | 10.51% | 8.88% | 108.02% | -3.23% | -60.14% | 59.70% | 59.70% | 59.70% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Axsome Therapeutics
AXSM
|
9.51B Mid-cap | -0.45% | 4.37% | 42.32% | 57.95% | 30.66% | 122.97% | 216.35% | 282.39% | 2,961.10% | 2,485.23% | 2,485.23% |
|
Praxis Precision
PRAX
|
9.60B Mid-cap | -21.90% | -17.38% | -12.35% | 49.84% | -2.61% | 807.83% | 2,210.03% | 21.08% | -16.07% | -16.07% | -16.07% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 5.74% | -7.11% | -10.77% | -20.32% | -14.75% | 6.78% | -37.73% | -51.28% | 86.91% | 161.27% | 281.12% |
Ownership & Short Interest
Calculate Your Beam Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Beam Therapeutics stock price in Feb 2020 was $20.62, A $1,000.00 lump sum investment in Beam Therapeutics made 6 years ago would be worth approximately $1,433.07 today, representing a positive return of 43.31%. This translates to an annualized return (CAGR) of 5.85%.
6 Years 4 Months Investment Scenario (Feb 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BEAM's 52-week high and low?
- In the last 52 weeks, Beam Therapeutics reached a high of $36.44 (on January 12, 2026) and a low of $15.60 (on August 21, 2025).
- What is the market cap and P/E ratio for BEAM?
- Curious about Beam Therapeutics's size and valuation? Its market capitalization stands at 3.10B. When it comes to valuation, the P/E ratio (trailing twelve months) is -37.23, and the forward P/E (looking ahead) is -6.99.
- Does BEAM pay dividends? If so, what's the yield?
- As for dividends, Beam Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Beam Therapeutics's main competitors or similar companies to consider before investing?
When looking at Beam Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Axsome Therapeutics
AXSM9.51B Healthcare Biotechnology 122.97% 216.35% Praxis Precision
PRAX9.60B Healthcare Biotechnology 807.83% 2,210.03% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.78% -37.73% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Beam Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Beam Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -8.11%, the Debt to Equity ratio from the most recent quarter is 12.45, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for BEAM?
- Looking at Beam Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $140M. Compared to the same quarter last year (YoY), quarterly revenue grew by 279.50%, and quarterly earnings saw a YoY growth of 279.52%.
- How much of BEAM stock is held by insiders and institutions?
- Wondering who owns Beam Therapeutics stock? Company insiders (like executives and directors) hold about 1.36% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 103.68%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.